default author photo

David S. Hong

University of Texas at Houston - MD Anderson Cancer Center

1901 East Road, Unit 1950

Unit 1905

Houston, TX 77030

United States

SCHOLARLY PAPERS

2

DOWNLOADS

190

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Efficacy of Pembrolizumab in Patients with Advanced Rare Cancers

Number of pages: 41 Posted: 31 May 2019
University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, Baylor College of Medicine, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston, Health Science Center at Houston (UTHealth), MD Anderson Cancer Center, Department of Radiology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Thoracic/Head and Neck Medical Oncology, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas Rio Grande Valley (UTRGV) (Formerly University of Texas-Pan American), University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, R Simon Consulting, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - MD Anderson Cancer Center and University of Texas at Houston - MD Anderson Cancer Center
Downloads 152 (488,442)

Abstract:

Loading...

2.

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Number of pages: 48 Posted: 22 May 2019
University of Texas at Houston - MD Anderson Cancer Center, KU Leuven - University Hospitals Leuven, KU Leuven - University Hospitals Leuven, Government of the United Kingdom - Royal Marsden NHS Foundation Trust, University of Miami - Division of Gynecologic Oncology, NHS Foundation Trust - Northern Centre for Cancer Care, Sarah Cannon Research Institute, Catholic University of Louvain (UCL), King’s College London, Cardiff University, University College London - UCL Cancer Institute, Ambroise Paré Central University Hospital, University of Liège - University Hospital of Liège, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, The University of Manchester, Genmab US, Inc., Genmab US, Inc., Genmab Copenhagen, Genmab US, Inc., University of Copenhagen - Rigshospitalet and University of Texas at Houston - MD Anderson Cancer Center
Downloads 38 (1,209,354)

Abstract:

Loading...